Electropharmacological effects of a spironolactone derivative, potassium canrenoate, assessed in the halothane-anesthetized canine model

Journal of Pharmacological Sciences

Volumn 96, Issue 4, 2004, Pages 436-443

  Sugiyama, Atsushi ^a   Satoh, Yoshioki ^a   Takahara, Akira ^a   Ando, Kentaro ^a   Wang, Kai ^a   Honsho, Sachiko ^a   Nakamura, Yuji ^a   Hashimoto, Keitaro ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Canrenoate; Monophasic action potential; QT prolongation; Spironolactone; Torsades de pointes

Indexed keywords

ALDOSTERONE RECEPTOR; CANRENOATE POTASSIUM; HALOTHANE; HEPARIN CALCIUM; POTASSIUM CHANNEL HERG; SPIRONOLACTONE; THIOPENTAL;

ACTION POTENTIAL; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; ATRIOVENTRICULAR CONDUCTION; BLOOD PRESSURE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE REFRACTORY PERIOD; HEART OUTPUT; HEART PROARRHYTHMIA; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE CONDUCTION; HEART VENTRICLE WALL; IN VIVO STUDY; MALE; NONHUMAN; POTASSIUM CURRENT; QT PROLONGATION; TORSADE DES POINTES; VASCULAR RESISTANCE;

EID: 12444283752     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.FPJ04025X     Document Type: Article

References (30)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
2. Briggs A, Holland W. Antifibrillatory effects of electrolyte-regulating steroids on isolated rabbit atria. Am J Physiol. 1959;197:1161-1164.
3. Coraboeuf E, Deroubaix E. Effect of a spironolactone derivative, sodium canrenoate, on mechanical and electrical activities of isolated rat myocardium. J Pharmacol Exp Ther. 1974;191:128-138.
4. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2001;37:1800-1807.
5. Caballero R, Moreno I, González T, Arias C, Valenzuela C, Delpon E, et al. Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels. Circulation. 2003;107:889-895.
6. Hashimoto K, Xue YX, Chen J, Akie Y, Eto K, Ni C, et al. Effects of class III antiarrhythmic drugs on ventricular arrhythmias in dogs. Exp Clin Cardiol. 1997;2:25-29.
7. Waldo AL, Camm AJ, de Ruyter H, Friedman PL, MacNeil DJ, Pauls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996;348:7-12.
8. Barrett TD, Hennan JK, Fischbach PS, O'Neill BP, Driscoll Jr EM Jr, Lucchesi BR. Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence. Br J Pharmacol. 2001;132:1493-1500.
9. Sugiyama A, Satoh Y, Shiina H, Takeda S, Hashimoto K. Torsadegenic action of the antipsychotic drug sulpiride assessed using in vivo canine models. J Cardiovasc Pharmacol. 2002;40:235-245.
10. Satoh Y, Sugiyama A, Chiba K, Tamura K, Hashimoto K. QT prolonging effects of sparfloxacin, a fluoroquinolone antibiotics, assessed in the in vivo canine model with the monophasic action potential monitoring. J Cardiovasc Pharmacol. 2000;36:510-515.
11. Sugiyama A, Hashimoto K. Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring. Toxicol Appl Pharmacol. 1998;152:261-269.
12. Satoh Y, Sugiyama A, Tamura K, Hashimoto K. Effects of a class III antiarrhythmic drug, dofetilide, on the in situ canine heart assessed by the simultaneous monitoring of hemodynamic and electrophysiological parameters. Jpn J Pharmacol. 1999;81:79-85.
13. Sugiyama A, Satoh Y, Hashimoto K. Acute effects of intravenously administered amiodarone assessed in the in vivo canine model. Jpn J Pharmacol. 2001;87:74-82.
14. Chiba K, Sugiyama A, Satoh Y, Shiina H, Hashimoto K. Proarrhythmic effects of fluoroquinolone antibacterial agents: In vivo effects as physiologic substrate for torsades. Toxicol Appl Pharmacol. 2000;169:8-16.
15. Usui T, Sugiyama A, Ishida Y, Satoh Y, Sasaki Y, Hashimoto K. Simultaneous assessment of the hemodynamic, cardiomechanical and electrophysiological effects of terfenadine on the in vivo canine model. Heart Vessels. 1998;13:49-57.
16. Bazett HC. An analysis of the time relations of electrogram. Heart. 1918;7:353-370.
17. Van de Water A, Verheyen J, Xhonneux R, Reneman RS. An improved method to correct the QT interval of the electrocardiogram for change in heart rate. J Pharmacol Methods. 1989;22:207-217.
18. Kr channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes. Jpn J Pharmacol. 2002;88:414-421.
19. Gochman N, Gantt CL. A fluorimetric method for the determination of a major spironolactone (aldactone) metabolite in human plasma. J Pharmacol Exp Ther. 1962;135:312-316.
20. Karim A. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab Rev. 1978;8:151-188.
21. Mironneau J. Calcium channel antagonist effects of spironolactone, an aldosterone antagonist. Am J Cardiol. 1990;65:7K-8K.
22. Dacquet C, Loirand G, Mironneau C, Mironneau J, Pacaud P. Spironolactone inhibition of contraction and calcium channels in rat portal vein. Br J Pharmacol. 1987;92:535-544.
23. Sorrentino R, Autore G, Cirino G, d'Emmanuele de Villa Bianca R, Calignano A, Vanasia M, et al. Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings. J Cardiovasc Pharmacol. 2000;36:230-235.
24. +-ATPase in human placental membranes and in erythrocytes. J Cardiovasc Pharmacol. 2003;42:32-36.
25. Cargnelli G, Trevisi L, Debetto P, Luciani S, Bova S. Effects of canrenone on aorta and right ventricle of the rat. J Cardiovasc Pharmacol. 2001;37:540-547.
26. Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Yoneyama M, Kugiyama K, et al. Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model. Circ J. 2002;66:758-762.
27. Sugiyama A, Ishida Y, Satoh Y, Aoki S, Hori M, Akie Y, et al. Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT prolonging drugs. Jpn J Pharmacol. 2002;88:341-350.
28. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation. 2001;103:2004-2013.
29. Takahara A, Sugiyama A, Satoh Y, Yoneyama M, Hashimoto K. Cardiovascular effects of Y-27632, a selective Rho-associated kinase inhibitor, assessed in the halothane-anesthetized canine model. Eur J Pharmacol. 2003;460:51-57.
30. Kr. Circulation. 1996;93:407-411.